E 6007

Drug Profile

E 6007

Alternative Names: E-6007

Latest Information Update: 10 Nov 2016

Price : $50

At a glance

  • Originator Eisai Inc
  • Developer EA Pharma; Eisai Inc
  • Class Small molecules
  • Mechanism of Action Integrin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ulcerative colitis
  • No development reported Inflammatory bowel diseases

Most Recent Events

  • 01 Oct 2016 Phase-II clinical trials in Ulcerative colitis in Japan (PO) (JapicCTI163437; Eisai pipeline, November 2016)
  • 01 Nov 2015 Eisai completes a phase I trial in Inflammatory bowel diseases in Japan (In volunteers) (NCT02268838)
  • 31 Oct 2014 Phase-I clinical trials in Inflammatory bowel disease (In volunteers) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top